Table 3. Multivariable linear mixed effects analysis of QT interval with study-specific correction.
| Variable | Number of observations | Adjusted estimate (95% CI) | p-value |
|---|---|---|---|
| Change from baseline after ASAQ | 1,361 | 16.87 (14.97 to 18.78) milliseconds | <0.001 |
| Change from baseline versus ASAQ, by antimalarial treatment arm | 5,192 | ||
| ASAQ | 1,361 | Reference | |
| CQ | 347 | 5.07 (1.39 to 8.75) milliseconds | 0.0069 |
| DP | 1,429 | 2.34 (0.01 to 4.67) milliseconds | 0.0495 |
| AL | 924 | −11.32 (−13.96 to −8.67) milliseconds | <0.001 |
| PA | 1,131 | −18.03 (−20.51 to −15.56) milliseconds | <0.001 |
| Baseline measurement versus ASAQ, by antimalarial treatment arm | 2,674 | ||
| ASAQ | 720 | Reference | |
| CQ | 173 | −1.46 (−5.43 to 2.50) milliseconds | 0.4693 |
| DP | 716 | 1.29 (−1.07 to 3.64) milliseconds | 0.2833 |
| AL | 499 | −0.33 (−3.04 to 2.37) milliseconds | 0.8091 |
| PA | 566 | −0.92 (−3.49 to 1.64) milliseconds | 0.4808 |
| Body temperature, per 1°C increase | 5,192 | −2.74 (−3.33 to −2.15) milliseconds | <0.001 |
| Female sex, by age group | 1,215 | ||
| 0.5 to <5 years | 215 | Reference | |
| 5 to <10 years | 419 | −8.96 (−11.75 to −6.17) milliseconds | <0.001 |
| 10 to <15 years | 294 | −7.77 (−10.81 to −4.74) milliseconds | <0.001 |
| ≥15 years | 287 | −8.89 (−12.17 to −5.61) milliseconds | <0.001 |
| Male versus female sex, by age group | 1,459 | ||
| 0.5 to <5 years* | 265 | −3.14 (−6.19 to −0.10) milliseconds | 0.0431 |
| 5 to <10 years* | 413 | 3.79 (−0.02 to 7.61) milliseconds | 0.0514 |
| 10 to <15 years* | 329 | 1.28 (−2.79 to 5.36) milliseconds | 0.5381 |
| ≥15 years* | 452 | −10.05 (−14.09 to −6.00) milliseconds | <0.001 |
* Coefficient to be added to female coefficient of same age group.
AL, artemether–lumefantrine; ASAQ, artesunate–amodiaquine; CQ, chloroquine; DP, dihydroartemisinin–piperaquine; PA, pyronaridine–artesunate.